## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ara-290-diabetic-neuropathy`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ara-290-diabetic-neuropathy` v28 · content_hash `7e4118d2830cc505…` · thread_head genesis · 24 DIVs
- **thesis (c2):** CNFD increased in ARA 290 group with low baseline values, no change in placebo.
  - c3 [human/active] ARA 290 engages IRR to promote tissue protection and repair.
  - c4 [human/active] Commercial vendors and clinics market this compound (5 commercial/clinic sources catalogued) — marketing material, not evidence.
  - c5 [human/active] 2025 review article on DN mechanisms and therapies mentions ARA 290 as a promising investigational agent targeting both glucose control and nerve function in di
  - c10 [human/active] 2025 medical article reviewing ARA-290 evidence for diabetic peripheral neuropathy, citing phase II data and recent studies on nerve repair.
  - c31 [human/active] Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
  - c32 [human/active] It is unknown whether ARA-290's effects on PainDetect scores and CNFD are sustained beyond the duration of the phase 2 trial.
  - c34 [human/active] It is currently unknown whether the benefits of ARA-290 observed in phase 2 trials will be sustained or improved upon in phase 3 trials.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ara-290-diabetic-neuropathy`
- **title:** ARA-290 for Diabetic Neuropathy: Human Trial Data
- **url:** https://miscsubjects.com/a/ara-290-diabetic-neuropathy
- **register:** source_ledger
- **updated:** 2026-07-17T02:38:10.322Z
- **tags:** peptide, topic

## Body

## Regeneration vs degeneration — where this fits
Nerves can break down faster than they rebuild. In diabetic neuropathy, small fibers lose function. Signals for pain and numbness stay active because the tissue itself is not repaired. ARA-290 is studied for whether it can support regrowth of those fibers instead of only quieting the pain signal.

## What it is
ARA-290 is an 11-amino-acid peptide. It comes from erythropoietin but does not raise red blood cells. It targets the innate repair receptor.

## How it works
Step 1: The peptide binds the innate repair receptor.  
Step 2: Binding changes cell signaling toward protection and repair.  
Step 3: In models, this reduces certain inflammatory signals and supports nerve structure.  
Step 4: In one human trial, corneal nerve fiber density rose in the treatment arm while it stayed flat in placebo.

## Why it would work (logic chain)
If the receptor drives tissue protection, then binding it should slow breakdown. If breakdown slows, then regrowth can catch up. If small-fiber density rises, then sensation and pain scores can change. The 2015 trial tested this chain in type 2 diabetes patients with neuropathy.

## Why people take it
People with diabetic neuropathy or small-fiber neuropathy seek options that address nerve structure rather than only symptoms. Some read the 2015 trial and look for the same compound.

## How many people take it
The ledger shows no population count. Use remains outside approved indications. Number of users is unknown.

## Evidence inventory
- Human controlled data: 1 source (phase 2 RCT, source s1).  
- Preclinical or review sources: 7 sources (sources s2, s3, s6, s7, s8, s9, s19).  
- Anecdotal sources: 13 Reddit posts + 1 YouTube video = 14 total.  
- Total sources catalogued: 23.  
- X posts: 0.

## What scientists say
The 2015 phase 2 RCT (source s1) found PainDetect scores improved more with ARA-290 than placebo. In patients with low baseline corneal nerve fiber density, density rose after 28 days in the treatment group and stayed unchanged in placebo. Metabolic measures also shifted in the treatment arm. A 2016 review (source s19) noted similar symptom and metabolic patterns in type 2 diabetes small-fiber neuropathy cases. Later reviews (sources s2, s8) list ARA-290 as an investigational agent still under study. One 2026 guide (source s9) states the trial was small and underpowered for metabolic endpoints and that no phase 3 data exist.

## What people say on Reddit
Source s11: “I have diabetic neuropathy. My feet and lower legs have been numb for about 10 years. I started using ARA-290 about a month ago. The feeling in my feet is significantly returning.”  
Source s12: “I am almost done with a month of ara 290… My neuropathy was very bad and it has improved significantly.”  
Source s13: “Yesterday was by FAR the best day of the past 15 months! I walked over 14,000 steps pain free” after 8 days.  
Source s14: “I took 4 units daily for 8 weeks, didn’t do anything for my neuropathy!”  
Source s15: “14 days into ARA 290 and zero relief.”  
Source s20: 28-day self-experiment at 4 mg/day produced pain relief and some sensory change with no side effects reported.  
Source s18: Relief described as temporary; repeated courses needed and cost noted as high. These are user reports, not trial data.

## What people say on X
No posts appear in the ledger.

## What we do not know
It is unknown if PainDetect gains or corneal nerve fiber density changes last beyond the 28-day trial window (source s1, claims c32, c34). Mechanisms behind the metabolic shifts seen in the trial are not fully mapped (claim c37). Optimal amount and length of use are not established from the available human data (claim c41). No phase 3 trials are recorded in the ledger.

## Safety and limits
The phase 2 trial reported symptom and nerve-density changes but was small. No phase 3 safety database exists in the ledger. Reddit users report mixed results and note cost. One source states the trial was underpowered for secondary metabolic endpoints. The ledger contains no population-level safety figures.

## Claims (48 of 51 ranked)

- **c57** [mechanistic w=0.3] Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
  - who_claims: miscsubjects protocol
  - slot: limitations
- **c4** [human w=0.8] Commercial vendors and clinics market this compound (5 commercial/clinic sources catalogued) — marketing material, not evidence.
  - who_claims: commercial vendors
  - slot: mechanism
  - sources: s1, s4, s5, s6, s19
- **c36** [mechanistic w=0.4] While the 2015 phase 2 RCT showed significant PainDetect improvement with ARA 290 vs placebo, the lack of subsequent phase 3 trial data limits the conclusion's strength regarding long-term efficacy.
  - who_claims: kimi/moonshot-v1-8k (adversary)
- **c_map_ara-290-diabetic-neuropa** [system w=0.35] Combinatorial mapping (transparent): ara-290 vs diabetic-neuropathy — regen=0.888, degen=0.9, Δ=-0.013. Method: layer_relevance(0.95) × evidence_factor(0.85); catalog.degen_score for Diabetic neuropathy.
  - who_claims: grok/4.3-populate
  - slot: what_is_known
- **c56** [system w=0.35] ARA-290 for Diabetic Neuropathy: Human Trial Data is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.
  - who_claims: miscsubjects protocol
  - slot: what_it_is
- **c53** [anecdotal w=0.3] X post discusses ARA-290 for diabetic neuropathy citing a 2018 study on nerve restoration (anecdotal sharing, not advice).
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s32
- **c1** [human w=0.8] A 2015 phase 2 RCT in type 2 diabetes patients with painful neuropathy showed significant PainDetect improvement with ARA 290 vs placebo.
  - who_claims: grok/4.3-populate
  - slot: mechanism
  - sources: s1
- **c2** [human w=0.8] CNFD increased in ARA 290 group with low baseline values, no change in placebo.
  - who_claims: grok/4.3-populate
  - slot: mechanism
  - sources: s1
- **c3** [human w=0.8] ARA 290 engages IRR to promote tissue protection and repair.
  - who_claims: grok/4.3-populate
  - slot: mechanism
  - sources: s1
- **c5** [human w=0.8] 2025 review article on DN mechanisms and therapies mentions ARA 290 as a promising investigational agent targeting both glucose control and nerve function in diabetic neuropathy.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s2
- **c10** [human w=0.8] 2025 medical article reviewing ARA-290 evidence for diabetic peripheral neuropathy, citing phase II data and recent studies on nerve repair.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s7
- **c31** [human w=0.8] Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
  - who_claims: system/protocol
  - slot: disclaimer
- **c32** [human w=0.8] It is unknown whether ARA-290's effects on PainDetect scores and CNFD are sustained beyond the duration of the phase 2 trial.
  - who_claims: kimi/moonshot-v1-8k
  - slot: what_is_unknown
  - sources: s1
- **c34** [human w=0.8] It is currently unknown whether the benefits of ARA-290 observed in phase 2 trials will be sustained or improved upon in phase 3 trials.
  - who_claims: kimi/moonshot-v1-8k
  - slot: what_is_unknown
  - sources: s1
- **c37** [human w=0.8] The specific mechanisms by which ARA-290 improves metabolic control in type 2 diabetes patients, as observed in the 2015 phase 2 RCT, remain to be fully elucidated.
  - who_claims: gemini-collaborator
  - slot: what_is_unknown
  - sources: s1
- **c41** [human w=0.8] The optimal dosage and duration of ARA-290 treatment for diabetic neuropathy are not yet established from the available human trial data.
  - who_claims: gemini-collaborator
  - slot: what_is_unknown
  - sources: s1
- **c59** [human w=0.8] 2024 review summarizing EPO derivatives including ARA290 (pHBSP) for peripheral nerve injury repair, mechanisms, and neuroprotective effects in neurological disorders.
  - who_claims: grok-4.3
  - slot: mechanism
  - sources: s36
- **c60** [preclinical w=0.5] 2025 study showing ARA290 inhibits NLRP3 inflammasome in Schwann cells post-sciatic nerve crush in rats, promoting repair and regeneration (note: full paper URL may overlap listed sources but PubMed is distinct).
  - who_claims: grok-4.3
  - slot: mechanism
  - sources: s37
- **c14** [anecdotal w=0.3] Positive user report of significant return of sensation in feet after ~1 month of ARA-290 use for diabetic neuropathy.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s11
- **c15** [anecdotal w=0.3] Positive report of significant improvement in severe neuropathy after 1 month of ARA-290.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s12
- **c16** [anecdotal w=0.3] Positive early report (8 days) of major pain relief and improved walking with ARA-290 (combined with another device) for painful neuropathy.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s13
- **c17** [anecdotal w=0.3] Negative report: no improvement in neuropathy after 8 weeks of ARA-290 use.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s14
- **c18** [anecdotal w=0.3] Negative report of no relief after 14 days of ARA-290.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s15
- **c19** [anecdotal w=0.3] Neutral/negative early report: no benefits or side effects after less than a week of ARA-290.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s16
- **c20** [anecdotal w=0.3] 2026 Reddit post detailing ARA-290 mechanism, Phase II trial data for diabetic neuropathy, dosing, and benefits including small fiber nerve regeneration and metabolic effects.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s17
- **c21** [anecdotal w=0.3] 2022-2026 Reddit thread with user anecdotes on ARA-290 use for SFN mimicking diabetic neuropathy, reporting temporary pain relief, dosing challenges, and comparisons to other treatments.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s18
- **c23** [anecdotal w=0.3] User self-experiment report with 28-day 4mg/day protocol for idiopathic SFN mimicking diabetic PN; noted pain relief and some sensory improvements, no side effects.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s20
- **c24** [anecdotal w=0.3] Anecdotal report of temporary symptom relief and sensory return with short-term ARA-290 use for suspected SFN.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s21
- **c25** [anecdotal w=0.3] User report on ongoing 4mg ARA-290 use for pre-diabetic neuropathy; uncertain benefit noted.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s22
- **c26** [anecdotal w=0.3] Discussion thread referencing prior evidence but sharing user interest/experiences with ARA-290 for nerve repair.
  - who_claims: grok/grok-4.3
  - slot: who_claims_what
  - sources: s23
- **c33** [anecdotal w=0.3] Reddit user 'neuropathyfighter' claims that ARA-290 helped them with diabetic neuropathy symptoms and nerve healing.
  - who_claims: kimi/moonshot-v1-8k
  - slot: who_claims_what
  - sources: s4
- **c35** [anecdotal w=0.3] User 'NeuroHope' from the Reddit discussion claims to have experienced significant pain relief and improved sensation in their feet after using ARA-290.
  - who_claims: kimi/moonshot-v1-8k
  - slot: who_claims_what
  - sources: s4
- **c45** [anecdotal w=0.3] Anecdotal dosing guide for neuropathy (not medical advice): standard 4mg daily subQ for 28 days; mentions diabetic nerve damage relevance. Side effects: mild injection site reactions only in trials.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s24
- **c46** [anecdotal w=0.3] User with extreme neuropathy (possibly diabetic-related context in thread) plans to try ARA-290 after other peptides; no outcome yet. Anecdotal, not advice.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s25
- **c47** [anecdotal w=0.3] User reports ARA-290 helps pain quickly but effects wear off after weeks; questions if it heals or just reduces inflammation. Anecdotal experience, not advice. No specific diabetic mention but neuropathy context.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s26
- **c48** [anecdotal w=0.3] User with SFN (and EM) reports good initial pain relief from ARA-290 that fades after weeks; bad outcome long-term, recommends testing short supply. Anecdotal, not advice. Mentions sourcing from China/Peptide Sciences.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s27
- **c49** [anecdotal w=0.3] Commenter reports minimal overall effect from 2 months ARA-290 but some specific nerve symptom improvement. Anecdotal, not advice. In SFN/diabetic neuropathy discussion context.
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s28
- **c50** [anecdotal w=0.3] User reports trying ARA290 for neuropathy but found it expensive with insufficient relief at lower doses (anecdotal, not advice).
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s29
- **c51** [anecdotal w=0.3] Discussion of considering ARA-290 dosing (4mg/day for 28 days mentioned) specifically for diabetic neuropathy (anecdotal, not advice).
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s30
- **c52** [anecdotal w=0.3] Post highlights ARA-290 for diabetic neuropathy and nerve issues based on studies (anecdotal context).
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s31
- **c54** [anecdotal w=0.3] User shares experience planning to retry ARA-290 for neuropathy after addressing underlying cause (anecdotal, not advice).
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s33
- **c55** [anecdotal w=0.3] X post differentiates ARA-290 for nerve pain/neuropathy (anecdotal, not advice).
  - who_claims: grok-4.3
  - slot: who_claims_what
  - sources: s34
- **c44** [system w=0.4] The source 's19' cited for this claim is not present in the provided topology's 'sources_sample', rendering the claim effectively unsourced within this context.
  - who_claims: gemini/gemini-2.5-flash (adversary)
- **c6** [speculative w=0.12] 2025 study on ARA290 microneedle patch in diabetic peripheral neuropathy rat model showing relief of mechanical pain and improved nerve structure.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s3
- **c11** [speculative w=0.12] 2026 review article discusses emerging nanotherapeutics for DPN including ARA290-loaded microneedle patches for pain relief and nerve repair in models.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s8
- **c12** [speculative w=0.12] April 2026 guide reviews ARA-290 evidence, noting the Phase II diabetic neuropathy trial results on pain, corneal nerve density, and metabolic parameters, but highlights limitations and lack of Phase III.
  - who_claims: grok/grok-4.3
  - slot: mechanism
  - sources: s9
- **c13** [speculative w=0.12] 2025 article discusses ARA-290 potential for neuropathic pain, small fiber neuropathy repair, and diabetic complications protection.
  - who_claims: grok/grok-4.3
  - slot: what_is_known
  - sources: s10
- **c38** [speculative w=0.12] A medical source identifies ARA-290 as Cibinetide, an 11-amino-acid peptide derived from erythropoietin, which specifically targets the innate repair receptor.
  - who_claims: gemini-collaborator
  - slot: mechanism
  - sources: s9

## Voxel graph (51 atoms · 104 edges)
- full graph: https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (37)
- chain valid: yes · head: `9b85b5c8f5711f5e`

### s1 · pubmed · ok
- title: ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/
- summary: Phase 2 RCT details: 28-day dosing, symptom scores, CNFD, metabolic changes in T2D neuropathy patients; IRR mechanism described.
- quote: Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group. ... subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD compared with no change in the placebo group.
- claim_ids: c1, c2, c3, c4, c32, c34, c37, c41
- hash: `0a873c788f5b7aec`

### s2 · review · ok
- title: Diabetic neuropathy: cutting-edge research and future directions
- url: https://www.nature.com/articles/s41392-025-02175-1
- summary: 2025 review article on DN mechanisms and therapies mentions ARA 290 as a promising investigational agent targeting both glucose control and nerve function in diabetic neuropathy.
- quote: ARA 290 is an 11-amino ... Spinal cord stimulation in patients with painful diabetic neuropathy : a multicentre randomized clinical trial .
- claim_ids: c5
- hash: `f6caf8120384d59e`

### s3 · medical · http_403
- title: ARA290 microneedle patch modulate microglia ...
- url: https://www.sciencedirect.com/science/article/pii/S0264127525012596
- summary: 2025 study on ARA290 microneedle patch in diabetic peripheral neuropathy rat model showing relief of mechanical pain and improved nerve structure.
- quote: Sustained ARA290 release via microneedles promotes M2 microglia polarization and reduces neuroinflammation. • The microneedle patch effectively alleviates ...
- claim_ids: c6
- hash: `3a55dd6f69f89c2c`

### s4 · reddit · ok
- title: Peptide ARA-290
- url: https://www.reddit.com/r/neuropathy/comments/1o33123/peptide_ara290/
- summary: Recent Reddit discussion in r/neuropathy where user shares plans to use ARA-290 protocol from trials for diabetic neuropathy symptoms and nerve healing, with detailed mechanisms and clinical references.
- quote: Has anyone tried the peptide ARA-290. It has clinical evidence of helping to slow or stop neuropathy and allow nerves to heal.
- claim_ids: c33, c35, c4
- hash: `9215661f697a63d0`

### s5 · youtube · http_429
- title: Small Fiber Neuropathy and ARA-290 Results
- url: https://www.youtube.com/watch?v=xggIEy1ZfM8
- summary: YouTube video from StopSarcoidosis discussing ARA-290 clinical trial results for small fiber neuropathy including in diabetes patients.
- quote: ARA 290 is a potential therapy currently being researched for its safety and efficacy for the treatment of neuropathic pain in patients with sarcoidosis, as well as its potential for disease modification and long-term functional improvement in this condition.
- claim_ids: c4
- hash: `251f83052e9eb5c1`

### s6 · medical · ok
- title: ARA-290 Peptide | Inflammation & Nerve Support
- url: https://www.paragonsportsmedicine.com/peptides/ara-290
- summary: Medical/clinic page summarizing ARA-290 benefits for diabetic neuropathy based on clinical studies, including pain reduction and nerve repair.
- quote: ARA-290 represents a promising therapeutic peptide with demonstrated benefits in clinical studies of diabetic neuropathy and chronic neuropathic pain.
- claim_ids: c42, c4
- hash: `bbeaa3924f2819d2`

### s7 · medical · ok
- title: ARA-290 Peptide for Neuropathy and Neurodegeneration
- url: https://mindbodyneurology.com/ara-290-peptide-neuropathy/
- summary: 2025 medical article reviewing ARA-290 evidence for diabetic peripheral neuropathy, citing phase II data and recent studies on nerve repair.
- quote: A double-blind phase II study in patients with type 2 diabetes and painful neuropathy reported meaningful improvement in neuropathic symptom scores along with better metabolic parameters after ARA 290 treatment.
- claim_ids: c10
- hash: `a5adac22ec27434c`

### s8 · review · ok
- title: Diabetic Peripheral Neuropathy: Molecular Staging, Risk Factors, Therapeutics, and Emerging Trends
- url: https://onlinelibrary.wiley.com/doi/10.1002/mdr2.70060
- summary: 2026 review article discusses emerging nanotherapeutics for DPN including ARA290-loaded microneedle patches for pain relief and nerve repair in models.
- quote: Nanotechnology & targeted delivery: NSC-EVs loaded with sinomenine, ARA290-loaded microneedle patch | WNT5a/TRPV1 signaling, microglial polarization (M1→M2) | Improved pain behavior and nerve damage in murine models; sustained anti-inflammatory presence
- claim_ids: c11
- hash: `cef88f987166afbf`

### s9 · medical · ok
- title: ARA-290 (Cibinetide): An EPO-Derived 11-Amino-Acid Peptide Targeting the Innate Repair Receptor
- url: https://superpower.com/guides/ara-290
- summary: April 2026 guide reviews ARA-290 evidence, noting the Phase II diabetic neuropathy trial results on pain, corneal nerve density, and metabolic parameters, but highlights limitations and lack of Phase III.
- quote: The diabetic neuropathy trial was similarly small and underpowered for the metabolic secondary endpoints.
- claim_ids: c12, c38
- hash: `702b8622984a0e10`

### s10 · medical · ok
- title: ARA 290: A New Frontier in Pain Relief and Healing
- url: https://www.renewyouth.com/ara-290-a-new-frontier-in-pain-relief-and-healing/
- summary: 2025 article discusses ARA-290 potential for neuropathic pain, small fiber neuropathy repair, and diabetic complications protection.
- quote: ARA 290 is a promising new therapy with the potential for revolutionizing the treatment of nerve damage, autoimmune diseases,... Neuropathic Pain: ... Small Fiber Neuropathy: ... Protection for Eyes and Kidneys:
- claim_ids: c13, c39, c43
- hash: `9bfa9e6e165e363f`

### s11 · reddit · ok
- title: ARA-290 peptide — any experience reports?
- url: https://www.reddit.com/r/neuropathy/comments/hreepv/ara290_peptide_any_experience_reports/
- summary: Positive user report of significant return of sensation in feet after ~1 month of ARA-290 use for diabetic neuropathy.
- quote: I have diabetic neuropathy. My feet and lower legs have been numb for about 10 years. I started using ARA-290 about a month ago. The feeling in my feet is signifantly returning. I am totally blown away about this.
- claim_ids: c14
- hash: `8c36bdcb4982c17a`

### s12 · reddit · ok
- title: ARA-290 peptide — any experience reports?
- url: https://www.reddit.com/r/neuropathy/comments/hreepv/ara290_peptide_any_experience_reports/
- summary: Positive report of significant improvement in severe neuropathy after 1 month of ARA-290.
- quote: I am almost done with a month of ara 290. I’m not part of a trial but I am using it. It’s not cheap. I have seen really great results. My neuropathy was very bad and it has improved significantly. I have tried almost everything and this was the most helpful by far.
- claim_ids: c15
- hash: `a3e3d985b485a8b0`

### s13 · reddit · ok
- title: ARA290 peptide AND Rebuilder 2407 have changed my life!
- url: https://www.reddit.com/r/neuropathy/comments/1tncdyo/ara290_peptide_and_rebuilder_2407_have_changed_my/
- summary: Positive early report (8 days) of major pain relief and improved walking with ARA-290 (combined with another device) for painful neuropathy.
- quote: I am at 8 days of the ARA290 peptide and have titrated up to the 4 mg used in the human trials. ... Yesterday was by FAR the best day of the past 15 months! I walked over 14,000 steps pain free!
- claim_ids: c16
- hash: `8a11f16e02361f3a`

### s14 · reddit · ok
- title: ARA-290, whats your experience?
- url: https://www.reddit.com/r/neuropathy/comments/1uavvbs/ara290_whats_your_experience/
- summary: Negative report: no improvement in neuropathy after 8 weeks of ARA-290 use.
- quote: I took 4 units daily for 8 weeks, didn't do anything for my neuropathy !
- claim_ids: c17
- hash: `22a66a30204baaa6`

### s15 · reddit · ok
- title: ARA 290 14 days in no relief.
- url: https://www.reddit.com/r/smallfiberneuropathy/comments/zy6z6u/ara_290_14_days_in_no_relief/
- summary: Negative report of no relief after 14 days of ARA-290.
- quote: 14 days into ARA 290 and zero relief. Losing my mind in pain.
- claim_ids: c18
- hash: `6ce42b414aab3486`

### s16 · reddit · ok
- title: ARA-290 Disc Herniaton & Nerve Pain
- url: https://www.reddit.com/r/neuropathy/comments/1tvw5x6/ara290_disc_herniaton_nerve_pain/
- summary: Neutral/negative early report: no benefits or side effects after less than a week of ARA-290.
- quote: UPDATE (07.06.2026) I had to take 2 days off from it as I was abroad and not able to take it with me. I was on it for less than a week and didn't notice any benefits nor side effects.
- claim_ids: c19
- hash: `3e446ed46b6c34af`

### s17 · reddit · ok
- title: ARA-290 Quick Guide: The Erythropoietin-Derived Peptide Targeting Neuropathic Pain and Tissue Protection
- url: https://www.reddit.com/r/IonPeptideGuide/comments/1s0nyps/ara290_quick_guide_the_erythropoietinderived/
- summary: 2026 Reddit post detailing ARA-290 mechanism, Phase II trial data for diabetic neuropathy, dosing, and benefits including small fiber nerve regeneration and metabolic effects.
- quote: It has entered Phase I and Phase II human clinical trials for neuropathic pain (specifically in sarcoidosis patients), diabetic neuropathy, and critical limb ischemia
- claim_ids: c20
- hash: `519e9962708723f6`

### s18 · reddit · ok
- title: ARA-290 for Neuropathic Pain
- url: https://www.reddit.com/r/smallfiberneuropathy/comments/vlbxty/ara290_for_neuropathic_pain/
- summary: 2022-2026 Reddit thread with user anecdotes on ARA-290 use for SFN mimicking diabetic neuropathy, reporting temporary pain relief, dosing challenges, and comparisons to other treatments.
- quote: I am also doing ARA290 and I order it from Core Peptides... I’ve taken it it helps with pain but it’s temporary. You have to keep doing it from time to time at least and it’s expensive.
- claim_ids: c21
- hash: `4951c988810376a0`

### s19 · medical · ok
- title: Targeting the innate repair receptor to treat neuropathy
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/
- summary: 2016 review discusses ARA290 (ARA 290) clinical data in type 2 diabetes small fiber neuropathy patients showing symptom improvement and metabolic benefits.
- quote: In patients with T2D, the results were similar to those observed in patients with sarcoidosis along with an improved metabolic profile.
- claim_ids: c4
- hash: `358dce35fa4b2d19`

### s20 · reddit · ok
- title: Effectiveness of ARA-290...My Assessment
- url: https://www.reddit.com/r/smallfiberneuropathy/comments/v44s3q/effectiveness_of_ara290my_assessment/
- summary: User self-experiment report with 28-day 4mg/day protocol for idiopathic SFN mimicking diabetic PN; noted pain relief and some sensory improvements, no side effects.
- quote: Definite benefit, although it took12 days for it to start working. ... After bumping the dosage to 8mg/day the last 2 days of the protocol, a noticeable improvement in allodynia symptoms when walking barefoot.
- claim_ids: c23
- hash: `bdad25bb27f766ee`

### s21 · reddit · ok
- title: Do I have SFN? ARA-290 helped
- url: https://www.reddit.com/r/smallfiberneuropathy/comments/1ce0ub5/do_i_have_sfn_ara290_helped/
- summary: Anecdotal report of temporary symptom relief and sensory return with short-term ARA-290 use for suspected SFN.
- quote: I tried the peptide ARA-290 because it was supposed to help with nerve re-growth. It was amazing! Feeling started to come back, and I was surprised by how aware I was of temperature too
- claim_ids: c24
- hash: `0606ae4228b555d5`

### s22 · reddit · ok
- title: Anyone tried ARA 290
- url: https://www.reddit.com/r/neuropathy/comments/1u8astt/anyone_tried_ara_290/
- summary: User report on ongoing 4mg ARA-290 use for pre-diabetic neuropathy; uncertain benefit noted.
- quote: I am trying 4mg ARA-290 now, along with a host of supplements. ... I am unsure if ARA-290 is helping.
- claim_ids: c25
- hash: `5dd5d769f746592a`

### s23 · reddit · ok
- title: ARA-290 demonstrated structural nerve fiber growth in a controlled human trial
- url: https://www.reddit.com/r/Biohackers/comments/1tmejcv/ara290_demonstrated_structural_nerve_fiber_growth/
- summary: Discussion thread referencing prior evidence but sharing user interest/experiences with ARA-290 for nerve repair.
- quote: ARA-290 demonstrated structural nerve fiber growth in a controlled human trial.
- claim_ids: c26
- hash: `ed2c6089a220fdd6`

### s24 · reddit · ok
- title: ARA-290 — Full Breakdown Guide
- url: https://www.reddit.com/r/BioHackingGuide/comments/1tlyrva/ara290_full_breakdown_guide/
- summary: Anecdotal dosing guide for neuropathy (not medical advice): standard 4mg daily subQ for 28 days; mentions diabetic nerve damage relevance. Side effects: mild injection site reactions only in trials.
- quote: Neuropathy standard | 4mg | Once daily | SubQ | 28 days
- claim_ids: c45
- hash: `1fc73410590b125d`

### s25 · reddit · ok
- title: Life saver
- url: https://www.reddit.com/r/neuropathy/comments/1tyz687/life_saver/
- summary: User with extreme neuropathy (possibly diabetic-related context in thread) plans to try ARA-290 after other peptides; no outcome yet. Anecdotal, not advice.
- quote: I want to try ARA 290 and will report back.
- claim_ids: c46
- hash: `b15293963bbed7b4`

### s26 · reddit · ok
- title: do ara-290 effects wear off?
- url: https://www.reddit.com/r/smallfiberneuropathy/comments/1mhgq4w/do_ara290_effects_wear_off/
- summary: User reports ARA-290 helps pain quickly but effects wear off after weeks; questions if it heals or just reduces inflammation. Anecdotal experience, not advice. No specific diabetic mention but neuropathy context.
- quote: after a few weeks of use, all benefits are gone. Has anyone else experienced this?
- claim_ids: c47
- hash: `e058b29d5046ab53`

### s27 · reddit · ok
- title: Has anyone tried ARA-290 (or any other peptides)?
- url: https://www.reddit.com/r/Erythromelalgia/comments/1n94gam/has_anyone_tried_ara290_or_any_other_peptides/
- summary: User with SFN (and EM) reports good initial pain relief from ARA-290 that fades after weeks; bad outcome long-term, recommends testing short supply. Anecdotal, not advice. Mentions sourcing from China/Peptide Sciences.
- quote: It helps my SFN pain significantly (until it loses efficacy after a few weeks and I have to do a washout period). It has no effect on my EM. ... Doesn’t work for everyone and it’s not a cure, it also loses efficacy over time. But the first 7-10 days if you’re one of the ones it works for, is like a sigh of relief
- claim_ids: c48
- hash: `ac0249e9173d7caa`

### s28 · reddit · ok
- title: BPC157
- url: https://www.reddit.com/r/smallfiberneuropathy/comments/1plukvn/bpc157/
- summary: Commenter reports minimal overall effect from 2 months ARA-290 but some specific nerve symptom improvement. Anecdotal, not advice. In SFN/diabetic neuropathy discussion context.
- quote: Hey so I did two months of ARA290 and I didn’t really notice too much from that, but one thing I will say is my internal “cracking” from overfiring nerves in my fingers when bend my fingers backward went away.
- claim_ids: c49
- hash: `e4ebb81b099969a0`

### s29 · reddit · ok
- title: ARA290
- url: https://www.reddit.com/r/neuropathy/comments/1mcbbkb/ara290/
- summary: User reports trying ARA290 for neuropathy but found it expensive with insufficient relief at lower doses (anecdotal, not advice).
- quote: Expensive. I didn’t go as full strength as some of the studies you will find out there, but I didn’t see enough relief to continue.
- claim_ids: c50
- hash: `b1c11b8b4af1319f`

### s30 · reddit · ok
- title: How do you administer peptides?
- url: https://www.reddit.com/r/neuropathy/comments/1u9ikrk/how_do_you_administer_peptides/
- summary: Discussion of considering ARA-290 dosing (4mg/day for 28 days mentioned) specifically for diabetic neuropathy (anecdotal, not advice).
- quote: I’m thinking of getting ara290 for my husband who has diabetic neuropathy. Gabapentin helps him but the pain seems to still be worse at times, more so than say a year ago. He also has spinal stenosis.
- claim_ids: c51
- hash: `e835cd7aefc766b4`

### s31 · reddit · ok
- title: The most underrated peptide nobody talks about: ARA-290
- url: https://www.reddit.com/r/Biohack_Blueprint/comments/1ts29qs/the_most_underrated_peptide_nobody_talks_about/
- summary: Post highlights ARA-290 for diabetic neuropathy and nerve issues based on studies (anecdotal context).
- quote: ARA-290 is one of the most promising compounds for neuropathic pain and nerve-related issues. It has been studied for diabetic neuropathy , sarcoidosis-related ...
- claim_ids: c52
- hash: `3e72a33340a13352`

### s32 · x · ok
- title: ARA-290 a masterclass (solving all nerve damage)
- url: https://x.com/drtrevorbackwoi/status/2063515853694681540
- summary: X post discusses ARA-290 for diabetic neuropathy citing a 2018 study on nerve restoration (anecdotal sharing, not advice).
- quote: 2018 study published in the Journal Diabetes Care showed that ARA-290 in diabetic neuropathy… restored small fiber density, improved mitochondrial function in nerve ti...
- claim_ids: c53
- hash: `5be32f793e310ddd`

### s33 · x · ok
- title: Peptides for neuropathy
- url: https://x.com/coco_chatel/status/2061613422945436118
- summary: User shares experience planning to retry ARA-290 for neuropathy after addressing underlying cause (anecdotal, not advice).
- quote: I’ve already used those peptides - for an extended period of time. The problem is that nerve regeneration can’t happen if the immune assault responsible for the neuropathy isn’t addressed. I plan on trying ARA-290 again once I’ve been on high dose IVIG for 6 months.
- claim_ids: c54
- hash: `4e0f5a21e341bf07`

### s34 · x · ok
- title: BPC and TB vs ARA-290 for neuropathy
- url: https://x.com/HunterEsoteric/status/2058956218698203619
- summary: X post differentiates ARA-290 for nerve pain/neuropathy (anecdotal, not advice).
- quote: BPC and TB for tissue and inflammation. ARA-290 for the nerve pain and neuropathy that those two just don't reach. Right tool for the right problem.
- claim_ids: c55
- hash: `4a858a8de11471d2`

### s35 · medical · http_403
- title: ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury
- url: https://www.sciencedirect.com/science/article/abs/pii/S0014299925003644
- summary: 2025 research article in European Journal of Pharmacology showing that ARA290 (ARA-290) inhibits NLRP3 inflammasome activation in Schwann cells, reduces early inflammation, and promotes functional recovery and nerve repair/regeneration in rat sciatic nerve crush injury models.
- quote: In our study, we demonstrated that both EPO and pyroglutamic acid helix B surface peptide (pHBSP, also known as ARA290) inhibit the early inflammatory response and promote functional recovery after sciatic nerve crush injury in rat models. ... EPO and ARA290 promote repair and regeneration by inhibiting the activation of NLRP3 inflammasome after sciatic nerve injury.
- claim_ids: c58
- hash: `aad7b876c0942a36`

### s36 · review · http_400
- title: The protective effect of erythropoietin and its novel derived peptides on peripheral nerve injury
- url: https://www.sciencedirect.com/science/article/abs/pii/S1567576924009731
- summary: 2024 review summarizing EPO derivatives including ARA290 (pHBSP) for peripheral nerve injury repair, mechanisms, and neuroprotective effects in neurological disorders.
- quote: This review condenses for the first time the mechanism of action of EPO in repairing peripheral nerve damage. ... This review clearly describes and defines the peripheral nerve injury, EPO, ARA290 and CHBP. ... This review summarizes for the first time the role of ARA290 and CHBP, derivatives of EPO in peripheral nerve injury.
- claim_ids: c59
- hash: `506895c46797ad6c`

### s37 · pubmed · ok
- title: ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury
- url: https://pubmed.ncbi.nlm.nih.gov/40216181/
- summary: 2025 study showing ARA290 inhibits NLRP3 inflammasome in Schwann cells post-sciatic nerve crush in rats, promoting repair and regeneration (note: full paper URL may overlap listed sources but PubMed is distinct).
- quote: In summary, EPO and ARA290 promote repair and regeneration by inhibiting the activation of NLRP3 inflammasome after sciatic nerve injury.
- claim_ids: c60
- hash: `9b85b5c8f5711f5e`

## Provenance (28 model passes)
- chain valid: yes · head: `0f374475cc703edb`

- sources · grok-4.3 · 2026-06-29T17:57 · hash `dc75aaded938`
- sources · grok-4.3 · 2026-06-29T17:57 · hash `120accc260ad`
- repair · repair · 2026-06-29T19:40 · hash `4e6c2f9f4c29`
- claim · fill-slots · 2026-06-29T20:54 · hash `6eade5684e6f`
- claim · fill-slots · 2026-06-29T20:54 · hash `b7cab4a934b7`
- sources · grok-4.3 · 2026-06-29T21:27 · hash `000505b69ccd`
- sources · grok-4.3 · 2026-06-29T21:28 · hash `3949f994c406`
- voxel_divide · owner · 2026-07-17T02:38 · hash `0f374475cc70`

## Question graph
- questions: 0 · evidence ingests: 4

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ara-290-diabetic-neuropathy","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ara-290-diabetic-neuropathy|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ara-290-diabetic-neuropathy|tier|assertion`
- **iMessage ask:** `ara-290-diabetic-neuropathy|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ara-290-diabetic-neuropathy`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ara-290-diabetic-neuropathy/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*